GSK joins hands with apple research kit to enter the era of personalized "medicine making"

Source: bioprospecting 2015-7-15 according to the latest news from firstword Pharma, GSK and Purdue Pharma will use Apple's Research Kit framework for drug research and development, which is the first time for large pharmaceutical companies to use health application app for drug research and development Researchkit is a new application developed by apple in March this year Users can use Apple's app to upload data to help doctors and scientists conduct more accurate medical and health research At present, there are six applications involving asthma, diabetes, heart disease and other diseases GSK said in a statement that its main work in the next few months will focus on Integrating Research Kit data into clinical trials At this time, working with apple is the best time for large pharmaceutical companies to collect patient data In addition, Larry Pickett, CIO of Purdue pharmaceuticals, which is famous for Oxycontin painkillers, said: the company said it was looking to apply the tool to data collection in research and development There is no doubt that the impact of technology on health care is becoming more and more important, but it is not clear how technology affects health care People have been arguing about the impact of big data on pharmaceutical companies and how to use the advantages of information and data It is better to practice as soon as possible and draw conclusions from practice than to discuss constantly Industry insiders believe that GSK and Purdue Pharma, in collaboration with Apple's research kit, may help personalize research drugs Research Kit is an open source software platform that helps scientists collect medical data from iPhone users Apple says it has opened up a whole new world in contact with different races and data In addition to the cooperation with apple, the cooperation between big pharmaceutical companies and gene technology companies has become a beautiful landscape Earlier this year, for example, Roche's Genentech Co replaced the gene test data of 80000 Parkinson's patients with $60 million from 23andMe, and Pfizer also cooperated with 23andMe.